S-OA-K
Oral Abstracts - Session K - Histocompatibility & Clinical Cellular Therapy
BMT Tandem "Scientific" Meeting
Texas B (Gaylord Texan)
Chairs:
Steven M. Devine, MD
and
Ann M. Leen, PhD
Disclosures:
S. M. Devine,
Nothing To Disclose
A. M. Leen,
Nothing To Disclose
Safety and Clinical Efficacy of Rapidly-Generated Virus-Specific T Cells with Activity Against Adv, EBV, CMV, HHV6 and BK Virus Administered after Allogeneic Hematopoietic Stem Cell Transplant
Anastasia Papadopoulou, PhD, Baylor College of Medicine, Texas Children's Hospital, The Methodist Hospital;
Usha L Katari, Baylor College of Medicine, Texas Children's Hospital, The Methodist Hospital;
Ulrike Gerdemann, MD, Baylor College of Medicine, Texas Children's Hospital, The Methodist Hospital;
Ifigenia Tzannou, MD, Baylor College of Medicine, Texas Children's Hospital, The Methodist Hospital;
Caridad Martinez, MD, Baylor College of Medicine, Texas Children's Hospital;
Kathryn Leung, MD, Baylor College of Medicine, Texas Children's Hospital;
George Carrum, MD, Baylor College of Medicine, Texas Children's Hospital, The Methodist Hospital;
Adrian P. Gee, PhD, Baylor College of Medicine, Houston Methodist Hospital and Texas Children's Hospital;
Juan F. Vera, MD, Baylor College of Medicine, Houston Methodist Hospital and Texas Children's Hospital;
Robert A. Krance, MD, Baylor College of Medicine, Texas Children's Hospital, The Methodist Hospital;
Malcolm K. Brenner, MD, PhD, Baylor College of Medicine, Texas Children's Hospital, The Methodist Hospital;
Cliona M. Rooney, PhD, Baylor College of Medicine, Houston Methodist Hospital and Texas Children's Hospital;
Helen E. Heslop, MD, Baylor College of Medicine, Texas Children's Hospital, The Methodist Hospital;
Ann M. Leen, PhD, Baylor College of Medicine, Houston Methodist Hospital and Texas Children's Hospital
CMV-Specific T-Cell Therapy Improves Immune Reconstitution Following Unrelated Donor HSCT: Results of a Randomized Controlled Trial
Frederick Chen, NHS Blood and Transplant & Queen Elizabeth Hospital Birmingham NHS F.Trust;
Andrew Peniket, Oxford University Hospitals NHS Trust;
Eleni Tholouli, Central Manchester University Hospitals NHS Foundation Trust;
Adrian Bloor, The Christie NHS Foundation Trust;
Ronjon Chakraverty, Royal Free Hampstead NHS Trust;
David Marks, University Hospitals Bristol NHS Trust;
Antonio Pagliuca, King's College Hospital;
Nigel Russell, Nottingham City Hospital;
Kirsty Thomson, University College London Hospitals NHS Foundation Trust;
Heather Beard, NHS Blood and Transplant;
Katy Newton, Cell Medica Ltd;
Mohammad Raeiszadeh, NHS Blood and Transplant;
Simon Thomas, Cell Medica Ltd;
Paul Moss, School of Cancer Sciences and the Birmingham CRUK Centre;
Karl S. Peggs, UCL Cancer Institute
Third Party Donor Derived EBV Specific T Cells for the Treatment of Refractory EBV-Related Post-Transplant Lymphomas
Susan E. Prockop, MD, Memorial Sloan-Kettering Cancer Center;
Ekaterina S. Doubrovina, MD, PhD, Memorial Sloan-Kettering Cancer Center;
Juliet N. Barker, MBBS, FRACP, Memorial Sloan-Kettering Cancer Center;
Karim Baroudy, Memorial Sloan-Kettering Cancer Center;
Farid Boulad, MD, Memorial Sloan-Kettering Cancer Center;
Nancy A Kernan, MD, Memorial Sloan-Kettering Cancer Center;
Ramzi Khalaf, Memorial Sloan-Kettering Cancer Center;
Rachel Kobos, MD, Memorial Sloan-Kettering Cancer Center;
Esperanza Papadopoulos, MD, Memorial Sloan-Kettering Cancer Center;
Craig Sauter, MD, Memorial Sloan-Kettering Cancer Center;
Andromachi Scaradavou, MD, New York Blood Center;
Stephanie Suser, Memorial Sloan-Kettering Cancer Center;
Gloria Wasilewski, Memorial Sloan-Kettering Cancer Center;
Nicole Zakak, PNP, Department of Pediatrics, Bone Marrow Transplant Service, Memorial Sloan-Kettering Cancer Center;
Richard O'Reilly, MD, Memorial Sloan-Kettering Cancer Center
Clinical Trial Evaluating DC/AML Fusion Cell Vaccination in AML Patients Who Achieve a Chemotherapy-Induced Remission
Jacalyn Rosenblatt, MD, Beth Israel Deaconess Medical Center;
Richard M. Stone, MD, Dana-Farber Cancer Institute;
Lynne Uhl, MD, Beth Israel Deaconess Medical Center;
Donna Neuberg, ScD, Dana-Farber Cancer Institute;
Baldev Vasir, PhD, Dana-Farber Cancer Institute;
Poorvi Somaiya, Beth Israel Deaconess Medical Center;
Robin Joyce, MD, Beth Israel Deaconess Medical Center;
James D. Levine, MD, Beth Israel Deaconess Medical Center;
Vassiliki A. Boussiotis, MD, PhD, Beth Israel Deaconess Medical Center;
Jeffrey Zwicker, MD, Beth Israel Deaconess Medical Center;
Jon E. Arnason, MD, Beth Israel Deaconess Medical Center;
Katarina Luptakova, MD, Beth Israel Deaconess Medical Center;
David P. Steensma, MD, Dana-Farber Cancer Institute;
Daniel J. DeAngelo, MD, Dana-Farber Cancer Institute;
Ilene Galinsky, ANP, Dana-Farber Cancer Institute;
Carol Delaney, RN, Beth Israel Deaconess Medical Center;
Heidi Mills, BA, Beth Israel Deaconess Medical Center;
Emma Breault, Beth Israel Deaconess Medical Center;
Dina Stroopinsky, PhD, Beth Israel Deaconess Medical Center;
Donald Kufe, MD, Dana-Farber Cancer Institute;
David Avigan, MD, Beth Israel Deaconess Medical Center
The Impact of HLA-Mismatch Direction on the Outcome of Unrelated Bone Marrow Transplantation: A Retrospective Analysis from the JSHCT HLA Working Group
Junya Kanda, MD, PhD, Saitama Medical Center, Jichi Medical University;
Yoshinobu Maeda, MD, Okayama University Graduate School;
Kazuteru Ohashi, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital;
Takahiro Fukuda, MD, National Cancer Center Hospital;
Koichi Miyamura, Japanese Red Cross Nagoya First Hospital;
Shin-Ichiro Mori, MD, St Luke's International Hospital;
Yasuo Morishima, Aichi Cancer Center Research Institute;
Yoshiko Atsuta, MD, PhD, Nagoya University Graduate School of Medicine;
Yoshinobu Kanda, Saitama Medical Center, Jichi Medical University
Late Onset Colitis after Cord Blood Transplantation Is Consistent with Graft Versus Host Disease: Results of a Blinded Histopathological Review
Filippo Milano, MD, PhD, Fred Hutchinson Cancer Research Center;
Howard Shulman, MD, Fred Hutchinson Cancer Research Center;
Katherine A. Guthrie, PhD, Fred Hutchinson Cancer Research Center;
Ivy Riffkin, RN, Fred Hutchinson Cancer Research Center;
George B. McDonald, MD, Fred Hutchinson Cancer Research Center;
Colleen Delaney, MD, MSc, Fred Hutchinson Cancer Research Center
High Disease-Free Survival and Enhanced Protection Against Relapse after Double-Unit Cord Blood Transplantation (DCB-T) When Compared to Unrelated Donor Transplantation (URD-T) in Patients with Acute Leukemia, MDS and CML
Doris M. Ponce, MD, Memorial Sloan-Kettering Cancer Center;
Sean Devlin, PhD, Memorial Sloan-Kettering Cancer Center;
Marissa Lubin, BA, Memorial Sloan-Kettering Cancer Center;
Molly Maloy, MS, Memorial Sloan-Kettering Cancer Center;
Hugo Castro-Malaspina, M.D., Memorial Sloan-Kettering Cancer Center;
Jenna D. Goldberg, MD, Memorial Sloan-Kettering Cancer Center;
Ann A. Jakubowski, PhD, MD, Memorial Sloan-Kettering Cancer Center;
Esperanza Papadopoulos, MD, Memorial Sloan-Kettering Cancer Center;
Miguel-Angel Perales, MD, Memorial Sloan-Kettering Cancer Center;
Craig Sauter, MD, Memorial Sloan-Kettering Cancer Center;
Marcel R. M. van den Brink, MD, PhD, Memorial Sloan-Kettering Cancer Center;
James W Young, MD, FACP, Memorial Sloan-Kettering Cancer Center;
Nancy Kernan, MD, Memorial Sloan-Kettering Cancer Center;
Richard O'Reilly, MD, Memorial Sloan-Kettering Cancer Center;
Andromachi Scaradavou, MD, New York Blood Center;
Sergio Giralt, MD, Memorial Sloan-Kettering Cancer Center;
Juliet Barker, MBBS (Hons) FRACP, Memorial Sloan-Kettering Cancer Center
Analysis of 402 Cord Blood Units to Assess Factors Influencing Infused Viable CD34+ Cell Dose: The Critical Determinant of Engraftment
Duncan Purtill, MBBS, FRACP, FRCPA, Memorial Sloan-Kettering Cancer Center;
Katherine Smith, BA, Memorial Sloan-Kettering Cancer Center;
Richard Meagher, PhD, Memorial Sloan-Kettering Cancer Center;
Marissa Lubin, BA, Memorial Sloan-Kettering Cancer Center;
Andromachi Scaradavou, MD, New York Blood Center;
Cladd Stevens, MD, PhD, Memorial Sloan-Kettering Cancer Center;
Juliet N. Barker, MBBS, FRACP, Memorial Sloan-Kettering Cancer Center
